Novo Nordisk Signs Up To $1.3 Billion Deal for Access to Nanexa's Drug-Delivery Technology
Novo Nordisk (NVO) has entered into a deal worth up to €1.165 billion ($1.3 billion) with Swedish company Nanexa, granting the Danish pharmaceutical giant an exclusive global license to use Nanexa’s PharmaShell atomic layer deposition technology. The agreement allows Novo access to advanced drug-delivery systems that could enhance its capabilities in developing innovative therapies. PharmaShell is a proprietary platform designed for precise and controlled delivery of drugs at the cellular level, potentially improving efficacy while reducing side effects. This acquisition aligns with Novo’s strategy to expand into new therapeutic areas beyond traditional diabetes treatments.
Tickers: $NVO
Topics: drug delivery technology licensing deals pharmaceuticals